Form 8-K - Current report:
SEC Accession No. 0001600620-25-000047
Filing Date
2025-05-12
Accepted
2025-05-12 06:02:02
Documents
15
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K auph-20250512.htm   iXBRL 8-K 29267
2 EX-99.1 exhibit991_q12025earningsr.htm EX-99.1 135159
6 auphlogoregistered.jpg GRAPHIC 17097
  Complete submission text file 0001600620-25-000047.txt   322976

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20250512.xsd EX-101.SCH 1813
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20250512_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20250512_pre.xml EX-101.PRE 12532
17 EXTRACTED XBRL INSTANCE DOCUMENT auph-20250512_htm.xml XML 2720
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 25932377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)